Skye Bioscience Inc.(US:SKYE) Newsfileยท2025-11-22 01:57Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab, during the specified Class Period from November 4, 2024, to October 3, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Skye Bioscience's defendants misrepresented the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [5]. - Investors who purchased Skye securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by January 16, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].